Skip to main content

Cambium Bio Successfully Closes A$3.0M Financing Round

Written by Customer Service on . Posted in Public Companies.

SYDNEY, Dec. 05, 2024 (GLOBE NEWSWIRE) —  Cambium Bio Limited (ASX:CMB) (Cambium Bio, Cambium or Company), a clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications, is pleased to announce the successful completion of a A$3.0 million capital raising.

Key Highlights:

  • Capital raising of A$3.0 million completed at A$0.4637 per share, representing a 25% discount to the 5-day Volume Weighted Average Price (VWAP) up to and including 2 December 2024
  • Strong support from new strategic investor AventaCell Biomedical Corp and existing major shareholder Zheng Yang Biomedical Technology
  • Additional participation from Cambium Bio directors, CEO, and Australian institutional and sophisticated investors
  • Proceeds to advance Phase 3 clinical development of Elate Ocular® for dry eye disease

The capital raising, which was approved by shareholders at the Annual General Meeting held on 26 November 2024, comprises:

  • A$1.5 million strategic investment from AventaCell Biomedical Corp
  • A$0.25 million investment from Zheng Yang Biomedical Technology
  • A$0.146 million from Cambium Bio directors
  • A$1.054 million from Cambium Bio CEO, Australian institutional, sophisticated and other investors

Cambium Bio CEO, Karolis Rosickas, commented: “We are delighted with the strong support received in this capital raising, particularly from AventaCell Biomedical Corp as a new strategic investor. AventaCell’s global leadership in cell culture supplements using our human platelet technology makes them an ideal partner as we advance our therapeutic programs. The participation of our existing major shareholder ZYBT, along with directors and management, demonstrates continued confidence in our strategy and clinical and commercial potential of Elate Ocular®.”

Use of Funds

The proceeds will primarily support the advancement of Elate Ocular® through its registration-enabling Phase 3 clinical trials for dry eye disease, which are planned to commence in calendar Q2 2025. The funds will also provide working capital for the Company’s ongoing operations.

For further information, please contact:
Helen Leung
Corporate Secretary
info@cambium.bio
1 300 995 098

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.